.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Optimizing Systemic Therapy for Chronic Lymphocytic Leukemia

EP. 1: First-Line Therapy for Older Patients With CLL

January 4th 2019

EP. 2: Ibrutinib Versus FCR for Younger Patients With CLL

January 4th 2019

EP. 3: Novel Combination Therapies for CLL

January 4th 2019

EP. 4: Prognostic Factors in CLL

January 4th 2019

EP. 5: Emerging BTK Inhibitors for CLL

January 4th 2019

EP. 6: Real-World Data for CLL

January 4th 2019

EP. 7: Venetoclax + Rituximab in Relapsed CLL

January 4th 2019

EP. 8: Toxicity Management With Venetoclax for CLL

January 4th 2019

EP. 9: CD20-Targeted Antibodies With Novel Agents for CLL

January 4th 2019

EP. 10: Resistance to Venetoclax in CLL

January 4th 2019

EP. 11: Resistance to Ibrutinib in CLL

January 4th 2019

EP. 12: Duvelisib for Relapsed/Refractory CLL

January 4th 2019

EP. 13: CAR T-Cell Therapy for CLL

January 4th 2019

EP. 14: Take-Home Messages From ASH 2018 in CLL

January 4th 2019

EP. 15: Standardizing MRD Testing for CLL

January 4th 2019